2022 News

• 09.15.2022
  IR News

  Corporate Governance Report

• 09.12.2022
  Press Release IR News

  Notice of Personnel Change

• 09.12.2022
  IR News

  Santen Announces Change of Representative Director of the Board (change in CEO)

• 09.09.2022
  IR News

  Santen Announces Completion of Share Buyback

• 09.01.2022
  IR News

  Santen Announces Status of Share Buyback

• 08.04.2022
  IR News

  Santen Reports the 1st Quarter Fiscal 2022 Consolidated Performance

• 08.01.2022
  IR News

  Santen Announces Status of Share Buyback

• 07.29.2022
  Information

  Sustainability page on our website has been updated

• 07.22.2022
  IR News

  Notice on the Completion of Disposal of Treasury Shares Under Restricted Stock-Linked Remuneration Program

• 07.01.2022
  IR News

  Santen Announces Status of Share Buyback

• 06.29.2022
  Press Release IR News

  Santen Announces Endorsement of Task Force on Climate-Related Financial Disclosures (TCFD)

• 06.24.2022
  IR News

  Notice on the Disposal of Treasury Shares Under Restricted Stock-Linked Remuneration Program

• 06.20.2022
  Press Release IR News

  Santen receives manufacturing and marketing approval for the dry-eye treatment DIQUAS LX Ophthalmic Solution 3% in Japan - Improved formulation to reduce administration frequency to three-times daily, thus easing patients' burden -

• 06.10.2022
  Press Release IR News

  Santen and UBE announces U.S. Food and Drug Administration accepts resubmission of NDA for STN1011700 / DE-117 (omidenepag isopropyl) for treating glaucoma and ocular hypertension

• 06.01.2022
  IR News

  Santen Announces Status of Share Buyback

• 05.31.2022
  Press Release IR News

  Santen and ActualEyes start registering patients to participate in Phase II clinical trial (Phase IIa / PoC study, PHANTOM study) for Fuchs endothelial corneal dystrophy

• 05.17.2022
  IR News

  Santen Announces Change of Representative Director of the Board and Board of Director and Corporate Auditor Nominations

• 05.10.2022
  Press Release IR News

  Santen Received the Approval of Verkazia (Ciclosporin Eye Drops (III)), Providing New Solutions for Severe Vernal Keratoconjunctivitis in China

• 05.10.2022
  IR News

  Santen Announces Share Buyback

• 05.10.2022
  IR News

  Notice on the Formulation of a Share Buyback Policy

• 05.10.2022
  IR News

  Notice regarding Cancellation of 'Transition to a Holding Company Structure through Sole-share Transfer and Change in Fiscal Year'

• 05.10.2022
  IR News

  Santen Reports Fiscal 2021 Consolidated Performance

• 05.02.2022
  Press Release IR News

  Santen's Verkazia (Cyclosporine Ophthalmic Emulsion) 0.1% Now Available for the Treatment of Vernal Keratoconjunctivitis in Children and Adults in the United States

• 04.05.2022
  IR News

  Santen Announces Change of Major Shareholder

• 03.25.2022
  Information

  Santen switches all externally-sourced electricity for its plants and research facility in Japan to renewable energy-based power

• 03.23.2022
  IR News

  Santen Announces Change of Representative Director of the Board

• 03.03.2022
  IR News

  Santen to Present Latest Data on Omidenepag Isopropyl at AGS 2022

• 03.02.2022
  IR News

  Santen Wins Award for Excellence at the "Nikkei Integrated Report Award 2021"

• 02.28.2022
  Press Release IR News

  Santen Receives Marketing Approval in Japan for "PRESERFLO MicroShunt Glaucoma Drainage System Core Kit" to Treat Glaucoma

• 02.22.2022
  Press Release IR News

  Reinventing of Our Leadership Team to Shape the Future of Santen

• 02.10.2022
  Press Release IR News

  Santen certified as Digital Transformation Business Operator by Ministry of Economy, Trade and Industry

• 02.10.2022
  IR News

  Santen Reports the 3rd Quarter Fiscal 2021 Consolidated Performance

News Archive